Mark Coleman, Director at Axsome Therapeutics, Inc. (AXSM), bought 1,430 shares at $35.10 ($50K) on 2021-11-18, disclosed to the SEC on 2021-11-22.
Open-market purchase of $50k AXSM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.07 | 409 | $14K | 28.6% |
| 2 | $35.10 | 1,021 | $36K | 71.4% |
| Total | $35.09 avg | 1,430 | $50K | 100% |
| Filing → |
| AXSM | SELL | 2026-02-27 | $4.0M | — | Filing → |
| AXSM | BUY | 2025-09-09 | $263K | — | Filing → |
| AXSM | SELL | 2025-05-29 | $1.6M | — | Filing → |